HR3826

This bill expands Medicare coverage for diabetes outpatient self-management training. It allows health care practitioners beyond physicians to provide these services and increases covered training hours to an initial 10 hours and an additional 2 hours annually. This directly increases the addressable market for diabetes education and related medical devices, as more individuals will have access to covered training and technology. The Centers for Medicare & Medicaid Services (CMS) is also prohibited from limiting medically necessary training, ensuring broader access. The money trail indicates increased Medicare reimbursements for diabetes self-management training services. This directly benefits healthcare providers offering these services. Furthermore, the expansion of training and the prohibition on limiting medically necessary training will drive demand for diabetes monitoring devices and diagnostic testing. The Center for Medicare and Medicaid Innovation testing a virtual model for training also opens avenues for telehealth providers and digital health platforms specializing in diabetes management. Historically, similar expansions of Medicare coverage for specific conditions have led to increased utilization and revenue for companies in those segments. For example, when Medicare expanded coverage for continuous glucose monitors (CGMs) in 2017, companies like Dexcom ($DXCM) and Abbott Laboratories ($ABT) saw significant growth. Dexcom's stock price increased by over 30% in the year following the expanded coverage announcement. This bill creates a similar tailwind by broadening access to the training necessary to utilize these devices effectively and manage diabetes. Specific winners include companies manufacturing continuous glucose monitors (CGMs) and insulin pumps, as increased training will lead to higher adoption rates. Dexcom ($DXCM) and Abbott Laboratories ($ABT) are direct beneficiaries due to their CGM products. Medtronic ($MDT) also stands to gain from increased adoption of its insulin pumps and integrated diabetes management systems. Diagnostic companies like LabCorp ($LH) and Quest Diagnostics ($DGX) will see increased demand for diabetes-related testing as more patients engage in self-management. The bill does not specify direct appropriations but rather expands covered services, leading to increased reimbursement flows through existing Medicare mechanisms. This bill has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means. Given it has a Democratic sponsor and 7 cosponsors, it has moderate legislative momentum. The next step is committee consideration, which could involve hearings and markups. If it passes committee, it moves to a floor vote. The timeline for passage is uncertain but could occur within the current legislative session, potentially by late 2025 or early 2026. Implementation would follow CMS rulemaking, likely within 6-12 months of enactment.